AI-generated analysis. Always verify with the original filing.
Xilio Therapeutics, Inc. furnished its corporate investor presentation dated March 9, 2026, under Item 7.01, detailing its pipeline of masked immuno-oncology therapies, clinical milestones, and preliminary estimated cash balance of $137.5 million as of December 31, 2025, providing investors with updates on development timelines and financial position.
Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, o
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate slide presentation of Xilio Therapeutics, Inc. dated March 9, 2026 104 C